• FirefoxUpgrade to the new Firefox »
  •  Dow Down1.45% Nasdaq Down1.03%

    Cerus Corporation (CERS)

    5.34 Down 0.12(2.20%) Jan 30, 4:00PM EST
    |After Hours : 5.34 0.00 (0.00%) Jan 30, 5:18PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Cerus Corporation
    2550 Stanwell Drive
    Concord, CA 94520
    United States - Map
    Phone: 925-288-6000
    Website: http://www.cerus.com

    Index Membership:N/A
    Full Time Employees:115

    Business Summary 

    Cerus Corporation, together with its subsidiary, Cerus Europe B.V., operates as a biomedical products company in Europe, the Commonwealth of Independent States, and the Middle East. The company develops and commercializes the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication and designed to target and inactivate blood-borne pathogens, including viruses, bacteria, and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The company’s INTERCEPT Blood System for platelets is designed to inactivate blood-borne pathogens in platelets donated for transfusion; INTERCEPT Blood System for plasma is designed to inactivate blood-borne pathogens in plasma donated for transfusion; and INTERCEPT Blood System for red blood cells is designed to inactivate blood-borne pathogens in red blood cells donated for transfusion. Cerus Corporation markets its platelet and plasma systems through its direct sales force and distributors. The company has collaboration agreements with Baxter International, Inc. for the development and commercialization of the INTERCEPT Blood System. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Cerus Corporation

    Corporate Governance 
    Cerus Corporation’s ISS Governance QuickScore as of Jan 1, 2015 is 9. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 10; Compensation: 5.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. William M. Greenman , 48
    Chief Exec. Officer, Pres and Director
    Dr. Laurence M. Corash M.D., 71
    Co-Founder, Chief Medical Officer, Chief Scientific Officer, Sr. VP and Director
    Mr. Kevin D. Green , 43
    Chief Financial Officer and VP of Fin.
    Ms. Carol M. Moore , 65
    Sr. VP of Regulatory Affairs, Quality and Clinical
    Mr. Howard G. Ervin , 67
    VP of Legal Affairs
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders